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Refractory hypertension is an extreme phenotype of antihypertensive treatment failure.
Participants in the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study,
a large (n=30,239), population-based cohort were evaluated to determine the prevalence of
refractory hypertension and associated cardiovascular risk factors and comorbidities. Refractory
hypertension was defined as uncontrolled blood pressure (systolic/diastolic ≥ 140/90 mm Hg) on ≥
5 antihypertensive drug classes. Participants with resistant hypertension (systolic/diastolic
≥140/90 mm Hg on ≥ 3 or<140/90 mm Hg on ≥ 4 antihypertensive classes) and all treated
hypertensive participants served as comparator groups. Of 14,809 REGARDS participants
receiving antihypertensive treatment, 78 (0.5%) had refractory hypertension. The prevalence of
refractory hypertension was 3.6% among participants with resistant hypertension(n=2,144) and
41.7% among participants on 5 or more antihypertensive drug classes. Among all hypertensive
participants, African American race, male gender, living in the stroke belt or buckle, higher body
mass index, lower heart rate, reduced estimated glomerular filtration rate, albuminuria, diabetes
and history of stroke and coronary heart disease were associated with refractory hypertension.
Compared to resistant hypertension, prevalence ratios for refractory hypertension were increased
for African Americans (3.00, 95% CI 1.68 – 5.37) and those with albuminuria (2.22, 95% CI 1.40
– 3.52) and diabetes (2.09, 95% CI 1.32 – 3.31). The median 10-year Framingham risk for
coronary heart disease and stroke was higher among participants with refractory hypertension
compared to either comparator group. These data indicate that while resistant hypertension is
relatively common among treated hypertensive patients, true antihypertensive treatment failure is
rare.
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Introduction
Resistant hypertension, defined as uncontrolled blood pressure (BP) in spite of use of 3 or
more antihypertensive agents from different classes or controlled blood pressure with use 4
or more agents1, has an estimated prevalence of 10-15% among all treated hypertensive
patients.2-5 Multiple observational studies have found obesity, chronic kidney disease
(CKD), diabetes and older age to be associated with resistanthypertension.2-4,6-8 Patients
with resistant hypertension are more likely to have cardiovascular disease, manifest as
stroke, heart disease or congestive heart failure, compared to patients with more easily
controlled hypertension.6-11
Recently, an extreme phenotype of antihypertensive treatment failure or “refractory
hypertension” has been proposed. The initial description of refractory hypertension was
based on a retrospective analysis of patients with resistant hypertension referred to a
hypertension specialty clinic.12 Of 304 consecutive patients with confirmed resistant
hypertension, 29, or approximately 10%, were identified as having refractory hypertension
defined as failure to control systolic and diastolic BP to <140/90 mmHg after a minimum of
6 months of treatment by a hypertension expert. Overall, patients with refractory
hypertension were followed in the specialty clinic for an average of 11 months and were
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receiving an average of 6 antihypertensive agents from different classes. In that report,
patients with refractory hypertension had a higher prevalence of stroke history and prior
hospitalization for heart failure compared to patients with controlled resistant hypertension
(i.e., controlled BP on 4 or more antihypertensive agents from different classes).
The current study was designed to use a large, population-based cohort to determine the
prevalence of refractory hypertension. Additionally, we identified factors associated with
refractory hypertension and calculated the 10-year predicted risk for coronary heart disease
(CHD) and stroke for participants with refractory hypertension. To do so, we evaluated
participants with treated hypertension in the REasons for Geographic and Racial Differences
in Stroke (REGARDS) study.13 In order to characterize refractory hypertension, participants
with resistant hypertension and all participants treated with antihypertensive medication
were used as comparator groups.
Methods
Study Recruitment
The REGARDS study has been described previously.13 Briefly, adults ≥ 45 years of age
from all 48 continental US states and the District of Columbia were enrolled between
January 2003 and October 2007 (n=30,239). By design, the REGARDS study oversampled
African Americans and residents of the “stroke buckle” (coastal North Carolina, South
Carolina, and Georgia) and “stroke belt” (the remainder of North Carolina, South Carolina,
and Georgia as well as Alabama, Mississippi, Tennessee, Arkansas and Louisiana) for
enrollment. The current analysis was limited to REGARDS participants who reported a
history of hypertension and were taking antihypertensive medication (treated hypertension;
n=14,854). We subsequently excluded 45 participants who were missing systolic BP or
diastolic BP resulting in a final analytic cohort of 14,809 participants. The REGARDS study
protocol was approved at all participating centers by the Institutional Review Boards
governing research in human participants. All participants provided informed consent.
Data Collection
Baseline REGARDS study data were collected through a telephone interview, self-
administered questionnaire, and in-home examination. Participants' age, gender, smoking
status, education, annual household income, physical activity, alcohol consumption,
symptoms of depression, and self-report of prior physician diagnosed co-morbid conditions
(e.g., hypertension, diabetes, stroke, coronary heart disease [CHD]) were collected during
computer-assisted telephone interviews that were administered by trained staff. Symptoms
of depression were assessed by the 4-item Center for Epidemiologic Studies Depression
Scale (CES-D).14 During the in-home examination, trained professionals measured weight,
height, heart rate, and BP, an electrocardiogram (ECG) was performed, and blood and spot
urine samples were collected. Additionally, all prescription and over the counter pill bottles
were reviewed for medications taken over the prior 2 week period. High medication
adherence was defined as scoring ≤1 using the 4-item Morisky Medication Adherence Scale
(MMAS).15 Following the in-home examination, a self-administered questionnaire that
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included the Block 98 Food Frequency Questionnaire16 was given to the participant to
complete and mail back to the REGARDS study coordinating center.
Coronary heart disease was defined as a self-reported history of myocardial infarction or
revascularization procedure or ECG evidence of a myocardial infarction. Prevalent stroke at
baseline was defined as a self-reported history during the telephone interview. Current
smoking was defined as answering yes to the following two questions: “Have you smoked at
least 100 cigarettes in your lifetime?” and “Do you smoke cigarettes now, even
occasionally?” Physical activity was assessed with the question “How many times per week
do you engage in intense physical activity, enough to work up a sweat?” Response options
were “none”, “1 to 3 times per week”, or “≥ 4 times per week.” Participants who answered
“none” were considered physically inactive. Heavy alcohol consumption among men and
women was defined as > 14 and > 7 drinks per week, respectively. Diabetes was defined by
serum glucose ≥ 126 mg/dL for participants who fasted ≥ 8 hours or a serum glucose ≥ 200
mg/dL for those who did not fast prior to their blood draw or by self-report of a prior
diagnosis while not pregnant with concurrent use of insulin or oral hypoglycemic
medications. Body mass index (BMI) was calculated by dividing weight in kilograms by
height in meters squared. High-sensitivity C-reactive protein (hs-CRP) was measured by
particle enhanced immunonephelometry. High hs-CRP was defined as > 3 mg/L. Left
ventricular hypertrophy (LVH) was defined by the presence on the study ECG. The isotope-
dilution mass spectrometry (IDMS)-traceable serum creatinine method was used to estimate
glomerular filtration rate (eGFR) with the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation.17 Reduced eGFR was defined as levels < 60 ml/min/
1.73 m2. Albuminuria was defined by a urinary albumin to urinary creatinine ratio ≥ 30
mg/g. The food frequency questionnaire (FFQ) was used to estimate the average dietary
intake for one year prior to participants' in-home visits. Nutrient analysis was conducted by
Nutrition Quest. A DASH dietary score was created using methods similar to those
described by Fung et al.18 Depressive symptoms were defined by scoring ≥ 4 on the CES-D
scale. High medication adherence was defined as a score ≤ 1 on the MMAS. The 10-year
Framingham CHD and stroke risk scores were calculated for participants without a history
of CHD or stroke, respectively.19,20
Measurement of Blood Pressure and Definition of Refractory Hypertension
During the in-home examination, BP was measured twice by trained examiners following a
standardized protocol using aneroid sphygmomanometers. For at least five minutes,
participants sat with both feet on the floor prior to the first BP measurement. The two BP
measurements were taken thirty seconds apart. Hypertension was defined as systolic BP ≥
140 mmHg, diastolic BP ≥ 90 mmHg, or use of antihypertensive medication. BP control was
defined as systolic BP < 140 mmHg and diastolic BP < 90 mmHg. Based on the pill bottle
review, medications were coded into drug classes. Antihypertensive medication classes
included angiotensin converting enzyme-inhibitors (ACEi), alpha blockers, angiotensin-
receptor-blockers (ARB), beta blockers, calcium-channel blockers (CCB), central acting
agents, diuretics, mineralocorticoid receptor antagonists (MRA) and direct vasodilators.
One-pill-combinations were classified into the different respective classes. Medication
dosage information was not recorded. Resistant hypertension was defined as taking ≥ 3
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classes of antihypertensive medication with systolic BP ≥140 or diastolic BP ≥90 mmHg or
taking ≥ 4 classes of antihypertensive medication with systolic BP <140 and diastolic BP
<90 mmHg. Refractory hypertension was defined as taking ≥ 5 classes of antihypertensive
medication with systolic BP ≥140 mmHg or diastolic BP ≥ 90 mmHg.
Statistical Analysis
Characteristics were calculated separately for 3 groups of participants: (1) those with
refractory hypertension, (2) those with resistant hypertension, excluding those with
refractory hypertension, and (3) all individuals with hypertension taking antihypertensive
medications, excluding those with refractory hypertension (i.e., all treated individuals
receiving <5 classes of antihypertensive medication or individuals with controlled BP on ≥ 5
classes of antihypertensive medication). The prevalence of refractory hypertension was
calculated as the proportion of all participants taking ≥ 5 antihypertensive medication
classes among all participants with resistant hypertension and among all participants with
hypertension taking antihypertensive medication. Since we did not know if participants with
uncontrolled BP while receiving 3 or 4 classes of antihypertensive agents would have been
properly classified as having refractory hypertension or controlled resistant hypertension
with additional titration of treatment, we also calculated the prevalence of refractory
hypertension among all patients with resistant hypertension after excluding this group of
participants.
Next, we investigated factors associated with refractory hypertension. To do so, we
calculated prevalence ratios for refractory hypertension versus resistant hypertension and
separately versus all treated individuals with hypertension using Poisson regression with
robust standard errors. Factors investigated include age, race, sex, geographic region of
residence, income, education, reduced eGFR, albuminuria, diabetes, elevated hs-CRP, LVH,
history of stroke, history of CHD, physical activity, alcohol consumption, DASH diet score,
cigarette smoking, depressive symptoms, medication adherence, heart rate, and body mass
index. Initially, unadjusted prevalence ratios were calculated. Subsequently, prevalence
ratios were calculated after adjustment for age, race, sex, and geographic region of
residence. Due to the limited number of cases of refractory hypertension, adjustment for
additional covariates was not performed. Finally, we calculated the median 10-year CHD
and stroke risks for participants with refractory hypertension, resistant hypertension and all
treated hypertensive participants.21,22 Using quantile regression, we calculated the age, race,
sex, and geographic region of residence-adjusted difference in the median 10-year CHD and
stroke risks for individuals with refractory hypertension versus resistant hypertension and
versus all treated hypertensive participants, separately. Chained equations were used to
impute 10 data sets for missing data.23 Analyses were conducted in Stata/I.C. 12.1 (Stata
Corporation, College Station, TX).
Results
Prevalence of Refractory Hypertension
Of the 14,809 REGARDS participants receiving antihypertensive treatment, 78 had
refractory hypertension. This translates into an overall prevalence of refractory hypertension
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among all treated hypertensive participants of 0.5%. Among participants with resistant
hypertension (n=2,144), the prevalence of refractory hypertension was 3.6%. Among
participants with resistant hypertension (n=827), excluding the participants uncontrolled on
3 or 4 classes of antihypertensive agents, the prevalence of refractory hypertension was
9.6%. Among participants taking 5 or more classes of antihypertensive medication (n=187),
the prevalence of refractory hypertension was 41.7%.
Participant Characteristics
Antihypertensive medication use for the 78 participants with refractory hypertension is
shown in Figure 1. All participants with refractory hypertension were receiving a diuretic
and an ACEi or an ARB. The diuretics being used were predominately hydrochlorothiazide
(52.6%) or a loop diuretic (44.9%). Chlorthalidone was being used infrequently (3.9%) and
amiloride not at all. Only 18% were receiving a MRA. Participants with refractory
hypertension were more likely to be receiving a beta blocker (93.6%) compared to
participants with resistant hypertension (72.9%) or all treated hypertensive participants
(36.7%). Almost all participants with refractory hypertension (89.4%) had a high level of
medication adherence.
REGARDS participants with refractory hypertension were similar in age to their
counterparts with resistant hypertension and all treated hypertensives, but had a higher mean
BMI (Table 1). Participants with refractory hypertension were more likely to be African
American, male, a resident of the stroke belt or buckle states and have a lower
socioeconomic status based on household income and/or achieved education level. Small
differences in average heart rate were observed between the 3 groups. Additionally, those
with refractory hypertension more commonly had reduced eGFR, albuminuria, diabetes,
LVH and a history of stroke or CHD. Heavy alcohol consumption was lower in participants
with refractory hypertension while the DASH diet scores were similar in the 3 groups.
Factors Associated with Refractory Hypertension
In an unadjusted comparison to resistant hypertension, African American race, albuminuria,
and diabetes were associated with higher prevalence ratios for refractory hypertension
(Table 2). These associations persisted after adjusting for age, race, sex, and geographic
region.
In an unadjusted comparison to all hypertensive participants, African American race, male
gender, higher body mass index, reduced eGFR, albuminuria, diabetes, LVH, prior stroke
and prior CHD were associated with increased prevalence ratios of refractory hypertension
(Table 3). After multivariable adjustment, each of these factors except LVH remained
associated with refractory hypertension. A higher heart rate was associated with a lower
prevalence ratio for refractory hypertension both before and after multivariable adjustment.
In the adjusted model, living in the stroke buckle was associated with an increased
likelihood of having refractory hypertension with a prevalence ratio of 2.02 (95% CI 1.14 -
3.58).
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10-year CHD and stroke risk
Among participants without a history of CHD or stroke, the median Framingham 10-year
CHD risk score for participants with refractory hypertension was 50% higher than the risk
score for participants with resistant hypertension and more than double the risk score for all
treated hypertensive participants (Table 4). The median Framingham 10-year stroke risk
score for all participants with refractory hypertension was 28% higher than the risk score for
participants with resistant hypertension and more than double the risk score compared to all
treated hypertensive participants. After adjustment for age, race, sex, and geographic region
of residence, the median 10-year predicted risk of a CHD event and stroke event was 4.0
(95% CI: 0.8 – 7.2) and 5.1 (95% CI: 1.8 – 8.5) percentage points higher, respectively,
among those with refractory hypertension versus resistant hypertension. After adjustment,
the 10-year predicted CHD and stroke risk was 7.0 (95% CI: 4.6 – 9.5) and 8.1 (95% CI: 5.9
– 10.3) percentage points higher, respectively, among those with refractory hypertension
versus all participants treated for hypertension.
Discussion
In the current analysis of a large observational study including adults from across the US,
0.5% of participants receiving antihypertensive treatment and 3.6% of participants with
resistant hypertension had refractory hypertension. These findings represent the first
determination of antihypertensive treatment failure in a large, population-based cohort. The
observed prevalence of <1% of treated hypertensive individuals indicates that true
antihypertensive treatment failure may be extremely rare. However, the current findings also
indicate that as the number of medications needed to treat hypertension increases, the
likelihood of remaining uncontrolled increased dramatically, from 3.6% of those needing 4
or more classes of antihypertensive medications to over 40% of participants taking 5 or
more classes.
A prior description of patients with refractory hypertension was based on a retrospective
analysis of patients referred to the University of Alabama at Birmingham (UAB)
Hypertension Clinic.12 The term refractory hypertension was used to identify patients failing
maximum antihypertensive therapy, defined as patients whose BP remained uncontrolled
after a minimum of 6 months of treatment by a hypertension expert and in spite of use of a
multidrug regimen that included a long-acting diuretic (chlorthalidone) and a MRA (either
spironolactone or eplerenone). In that analysis, 10% of 304 patients originally referred to
UAB with resistant hypertension (i.e., uncontrolled on 4 medications) never achieved BP
control in spite of being adherent to regimens that included an average of 6 antihypertensive
medications from different classes. A lower prevalence of refractory hypertension (3.6%)
was observed among those with resistant hypertension in the current analysis of over 14,000
people with hypertension enrolled in this population-based study. The lower prevalence of
refractory hypertension in a generalized hypertensive cohort compared to patients referred to
a hypertension specialty clinic, undoubtedly, reflects the referral bias of more severe patients
being seen by hypertension specialists.
In the current analysis, participants with refractory hypertension were compared both to
participants with resistant hypertension and to all treated hypertensive participants in order
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to identify characteristics of individuals with refractory hypertension versus lesser degrees
of treatment resistance and to hypertension in general. After multivariable adjustment,
African American race, albuminuria and diabetes were strongly associated with having
refractory hypertension regardless of comparator group. Likewise, participants with
refractory hypertension had higher 10-year Framingham CHD and stroke risk scores than
those with resistant hypertension and all treated hypertensive participants. Additionally,
prior CHD and stroke were 2-3 times more common compared to all treated hypertensive
participants. Undoubtedly related to higher BP levels, participants with refractory
hypertension appear to have a markedly increased CV risk.
In the prior retrospective assessment of patients with refractory hypertension, a
distinguishing characteristic of this group was a significantly higher heart rate compared to
the participants with controlled resistant hypertension.12 This was interpreted to suggest
heightened sympathetic output as a potentially important underlying etiology of refractory
hypertension. In the current analysis, however, the mean heart rate was not different in the
participants with refractory hypertension compared to participants with resistant
hypertension and was even lower when compared to all treated hypertensive participants. A
lack of difference in heart rate may have been related, in part, to the greater use of beta
blockers in participants with refractory hypertension, which may have masked higher resting
heart rates. The absence of a higher heart rate would argue against differences in
sympathetic output between the 3 groups. However, an important difference between the
prior and current analyses is that individuals in the earlier study had more extreme cases of
refractory hypertension than those included in the current analysis. In the prior study, all of
the patients had been referred to a hypertension specialty clinic, their BP remained
uncontrolled on an average of 6 medications, including, in all patients, chlorthalidone and
spironolactone, and their hypertension was more severe compared to that documented in the
current study (mean systolic/diastolic BP: 168/94 vs. 155/83 mm Hg, respectively).12
Whether refractory hypertension is characterized by a higher resting heart rate needs
additional testing, including with 24-hr ambulatory monitoring of heart rate.
Recommendations for treating resistant hypertension are consistent in suggesting use of
multiple-drug regimens that include a long-acting diuretic and a MRA.1,24 Consistent with
these recommendations, in the current study, all participants classified as having refractory
hypertension were receiving a diuretic. However, in contrast with the recommendations,
only 18% of the participants with refractory hypertension were receiving a MRA. These
findings confirm the results of other analyses of large, population-based, observational
cohorts indicating underuse of MRAs for treatment of resistant hypertension. For example,
in an analysis of the National Health and Nutrition Examination Surveys (NHANES)
between 1988 and 2008, Egan et al found that as of 2005-2008, only 4.4% of participants
whose BP remained uncontrolled on 3 or more classes of antihypertensive medication were
receiving a MRA.3 Combined with the current findings, these observations highlight the
ongoing need to better inform practicing clinicians on how to construct effective multi-drug
antihypertensive regimens.
The design of the current study did not allow us to distinguish “apparent” from “true”
refractory hypertension. Ambulatory monitoring was not done and cases of white coat
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hypertension could not be identified. However, all BP measurements were done at the
participants' homes, which should have minimized white coat effects. Adherence was
assessed by the 4-item Morisky questionnaire, a validated measure of medication
adherence.16 A more objective measure, such as assessment of prescription refill rates,
however, may have found a lower adherence rate than indicated by self-report. This may be
particularly relevant to the current analysis as it is well established that adherence tends to
decrease as the number of prescribed pills increases. For example, a recent analysis of
patients referred to a German hypertension specialty clinic for resistant hypertension found
that only 40 of 76 patients (53%) were adherent with prescribed medications based on
liquid-chromatography-mass spectrometry analysis for antihypertensive drugs or their
corresponding metabolites in the patients' urine.25 Lastly, we were not able to quantify the
dosages for each of the prescribed agents, and so could not assess the degree to which under-
treatment contributed to apparent treatment failure. Having been able to account for these
causes of pseudo-treatment failure would have resulted in a prevalence of true refractory
hypertension even lower than the observed 0.5%. Such an anticipated reduction in the
prevalence further emphasizes our primary conclusion that even though apparent resistant
hypertension is common, true refractory hypertension is, in contrast, very rare.
The current study is strengthened by analysis of a large, rigorously characterized cohort,
including a relatively large number of participants with refractory hypertension. All
participants classified as having refractory hypertension were receiving a diuretic as part of
their antihypertensive regimen. Adherence was documented by use of a validated
questionnaire.16 Study limitations include not being able to exclude pseudo-refractory
hypertension secondary. While drug classes are included in the REGARDS dataset, dosages
of the individual agents are not. Accordingly, the current analysis may have overestimated
the cases of resistant and refractory hypertension because of use of less than optimal dosing.
Also not available were biological assessments known to be relevant to mechanisms of
resistant hypertension, including serum aldosterone and plasma renin levels and the presence
and severity of obstructive sleep apnea. Finally, with only 78 cases of refractory
hypertension we lacked statistical power to study its association with mortality and
cardiovascular disease outcomes during follow-up.
Perspectives
The current study characterizes a novel phenotype of antihypertensive treatment failure
referred to as refractory hypertension in a large nationwide cohort of African American and
white US adults. The study found that refractory hypertension is uncommon overall, but its
prevalence is high among patients prescribed a large number of antihypertensive
medications. The present study demonstrates underuse of MRAs in individuals failing to
achieve blood pressure control on other classes of antihypertensive medications. These
findings highlight the opportunity to further reduce the occurrence of refractory
hypertension through use of effective antihypertensive regimens, including preferential use
of spironolactone and long-acting thiazide diuretics such as chlorthalidone.
Calhoun et al. Page 9















Source(s) of Funding: This REGARDS study is supported by a cooperative agreement U01 NS041588 from the
National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and
Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official
views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health.
Representatives of the funding agency have been involved in the review of the manuscript but not directly involved
in the collection, management, analysis or interpretation of the data. The authors thank the other investigators, the
staff, and the participants of the REGARDS study for their valuable contributions. A full list of participating
REGARDS investigators and institutions can be found at http://www.regardsstudy.org
References
1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White
WB, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. American Heart Association Scientific
statement on resistant hypertension: diagnosis, evaluation, and treatment. Hypertension. 2008;
51:1403–1419. [PubMed: 18391085]
2. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension.
2011; 57:1076–1080. [PubMed: 21502568]
3. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment
resistant hypertension in the United States, 1988-2008. Circulation. 2011; 124:1046–1058.
[PubMed: 21824920]
4. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope
LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of
ambulatory blood pressure monitoring. Hypertension. 2011; 57:898–902. [PubMed: 21444835]
5. Roberie DR, Elliott WJ. What is the prevalence of resistant hypertension in the United States. Curr
Opin Cardiol. 2012; 27:386–391. [PubMed: 22596184]
6. Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlöf B, Poulter NR. on behalf of the ASCOT
investigators. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac
Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens. 2011; 29:2004–
2013. [PubMed: 21881528]
7. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, Severgnini B, Meani S, Magrini F,
Zanchetti A. High prevalence of cardiac and extracardiac target organ damage in refractory
hypertension. J Hypertens. 2001; 19:2063–2070. [PubMed: 11677373]
8. Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-four hour ambulatory blood pressure
monitoring pattern of resistant hypertension. Blood Press Monit. 2003; 8:181–185. [PubMed:
14624166]
9. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, Caldarella
MP, Neri M, Cuccurullo F, Mezzettti A. Cardiovascular outcome in treated hypertensive patients
with responder, masked, false resistant and true resistant hypertension. Am J Hypertens. 2005;
18:1422–1428. [PubMed: 16280275]
10. Isaksson H, Ostergren J. Prognosis in therapy-resistant hypertension. J Intern Med. 1994; 236:643–
649. [PubMed: 7989899]
11. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, O'Connor PJ, Selby
JV, Ho PM. Incidence and prognosis of resistant hypertension in hypertensive patients.
Circulation. 2012:1251635–1642.
12. Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, Cofield SS, Oparil S,
Calhoun DA. Refractory hypertension: definition, prevalence and patient characteristics. J Clin
Hypertens. 2012; 14:7–12.
13. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, Graham A, Moy CS, Howard
G. The reasons for geographic and racial differences in stroke study: objectives and design.
Neuroepidemiology. 2005; 25:135–143. [PubMed: 15990444]
14. Radloff LS. The CES-D Scale: a Self-report Depression scale for research in the general
population. Appl Psychol Meas. 1977; 1:385–401.
Calhoun et al. Page 10













15. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure
of medication adherence. Med Care. 1986; 24:67–74. [PubMed: 3945130]
16. Block G, Woods M, Potosky A, Clifford C. Validation of a self-administered diet history
questionnaire using multiple diet records. J Clin Epidemiol. 1990; 43:1327–1325. [PubMed:
2254769]
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P,
Van Lente F, Greene T, Coresh J, for the CKD-EPI (Chronic Kidney Disease Epidemilogy
Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;
150:604–612. [PubMed: 19414839]
18. Fung TT, Chiuve SE, McCullough ML, Rexrode KM, Logroscino G, Hu FB. Adherence to a
DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med. 2008;
168:713–720. [PubMed: 18413553]
19. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of
coronary heart disease using risk factor categories. Circulation. 1998; 97:1837–1847. [PubMed:
9603539]
20. D'Agostino S, Grundy S, Sullivan LM, Wilson P, for the CHD Risk Prediction Group. Validation
of the Framingham Coronary Heart Disease Prediction Scores: Results of a Multiple Ethnic
Groups Investigation. JAMA. 2001; (286):180–187. [PubMed: 11448281]
21. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: A risk profile from the
Framingham Study. Stroke. 1991; 22:312–318. [PubMed: 2003301]
22. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for
antihypertensive medication. The Framingham Study. Stroke. 1994; 25:40–43. [PubMed:
8266381]
23. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and
guidance for practice. Stat Med. 2011; 30:377–399. [PubMed: 21225900]
24. Krause T, Lovibond K, Caulfield M, McCormick T, Williams B, on behalf of the Guideline
Development Group. Management of hypertension: summary of NICE guidance. BMJ. 2011;
343:d4891. [PubMed: 21868454]
25. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant
hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;
31:766–774. [PubMed: 23337469]
Calhoun et al. Page 11














1. What is new?
• Refractory hypertension, a novel phenotype of antihypertensive treatment
failure, is defined as uncontrolled hypertension on 5 or more antihypertensive
medications.
• Evaluation of a large, population-based population indicates the prevalence of
refractory hypertension to be 0.5% of all participants being treated for
hypertension
2. What is relevant?
• Antihypertensive treatment failure is uncommon in a population-based cohort
indicating that hypertension can generally be controlled with continued titration
of antihypertensive treatments
3. Summary
Refractory hypertension identifies a phenotype of antihypertensive treatment failure. It is
uncommon in a population-based population but is characterized by an increased
prevalence of risk factors and comorbidities.
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Use of antihypertensive medication classes among study participants with refractory
hypertension (n=78). ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin
receptor blocker; Beta: beta antagonist; Alpha: alpha antagonist; MRA: mineralocorticoid
receptor antagonist; Central: central acting agent.
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Table 1
Characteristics of the REasons for Geographic and Racial Differences in Stroke (REGARDS) study
population with refractory hypertension, resistant hypertension and treated hypertension.
Characteristic Refractory hypertension Resistant hypertension* All treated hypertensives†
n = 78 n = 2,066 n = 14,731
Age (years) 66.0 ± 1.0 67.6 ±0.2 66.3 ± 0.1
African American (%) 80.8 60.0 50.5
Male (%) 53.8 48.8 42.8
Geographic Region (%)
 Stoke belt 38.5 34.3 35.2
 Stroke buckle 27.0 20.7 21.1
 Other region 34.5 45.0 43.7
Systolic blood pressure (mmHg) 154.8 ±1.7 141.5 ±0.4 131.2 ±0.1
Diastolic blood pressure (mmHg) 83.4 ±1.7 79.7 ±0.3 77.6 ±0.1
Heart rate (bpm) 64.0 ± 1.2 65.6 ±0.6 67.4 ± 0.2
Body mass index (kg/m2) 33.6 ± 0.8 32.2 ±0.1 30.7 ± 0.1
Household income, <$20,000 (%) 34.2 28.9 25.4
<High school education (%) 21.8 19.7 15.5
eGFR <60 ml/min/1.73m2 (%) 35.1 27.3 17.1
Albuminuria (ACR ≥30 mg/g) (%) 54.5 32.8 20.2
Diabetes (%) 67.4 45.1 30.8
hsCRP > 3 mg/L (%) 53.7 49.1 46.5
Left ventricular hypertrophy (%) 23.1 18.3 13.1
Prior stroke (%) 20.5 13.1 9.2
Prior coronary heart disease (%) 43.6 34.9 22.9
Physical activity (%) 52.9 56.1 61.1
Heavy alcohol consumption (%) 24.4 30.4 33.0
DASH diet score 23.5 ± 0.6 23.6 ±0.1 23.8 ± 0.0
Smoking status (%)
 Never 47.5 43.6 44.3
 Past 41.0 44.2 42.0
 Current 11.5 12.2 13.7
Depressive symptoms (%) 16.8 13.7 12.4
High medication adherence (%) 89.4 91.5 92.4
Numbers in table are mean ± standard error or percentage.
BPM, beats per minute; eGFR, estimated glomerular filtration rate; ACR, albumin creatinine ratio; hs-CRP, high sensitivity c-reactive protein
*All resistant hypertension participants except those with refractory hypertension.
†All treated hypertensive participants except those with refractory hypertension.
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Table 2
Prevalence ratios for refractory hypertension compared to individuals with resistant hypertension.
Characteristic Prevalence ratio (95% confidence interval)
Model 1 Model 2
Age, 10 years 0.81 (0.62 – 1.05) 0.90 (0.69 – 1.17)
African American versus white 2.72 (1.56 – 4.74) 3.00 (1.68 – 5.37)
Male versus female 1.22 (0.79 – 1.88) 1.51 (0.97 – 2.35)
Geographic Region
 Stroke belt versus non-belt 1.19 (0.76 – 1.86) 1.62 (0.98 – 2.67)
 Stroke buckle versus non-belt 1.39 (0.85 – 2.28) 1.89 (1.08 – 3.29)
Heart rate (bpm) 0.84 (0.56 – 1.25) 0.76 (0.51 – 1.13)
Body mass index (kg/m2) 1.15 (0.99 – 1.32) 1.10 (0.94 – 1.29)
Household income, <$20,000 1.27 (0.78 – 2.05) 1.17 (0.69 – 2.00)
<High school education 1.13 (0.67 – 1.91) 0.93 (0.53 – 1.64)
eGFR <60 ml/min/1.73m2 1.42 (0.89 – 2.28) 1.52 (0.94 – 2.45)
Albuminuria (ACR ≥30 mg/g) 2.36 (1.51 – 3.70) 2.22 (1.40 – 3.52)
Diabetes 2.44 (1.52 – 3.92) 2.09 (1.32 – 3.31)
hs-CRP 1.00 (0.97 – 1.02) 0.99 (0.97 – 1.02)
Left ventricular hypertrophy 1.33 (0.79 – 2.22) 1.18 (0.70 – 2.01)
Prior stroke 1.68 (0.98 – 2.86) 1.56 (0.91 – 2.67)
Prior coronary heart disease 1.42 (0.91 – 2.20) 1.59 (1.00 – 2.52)
Physical activity 0.88 (0.57 – 1.37) 0.84 (0.54 – 1.30)
Alcohol consumption 0.74 (0.45 – 1.24) 0.80 (0.47 – 1.36)
DASH diet score 0.698 (0.76 – 1.24) 1.04 (0.82 – 1.33)
Smoking status
 Never 1 (reference) 1 (reference)
 Past 0.88 (0.57 – 1.37) 0.91 (0.59 – 1.40)
 Current 0.94 (0.47 – 1.86) 0.83 (0.43 – 1.60)
Depressive symptoms 1.25 (0.70 – 2.25) 1.17 (0.65 – 2.12)
High medication adherence 0.78 (0.38 – 1.61) 0.77 (0.38 – 1.56)
BPM, beats per minute; eGFR, estimated glomerular filtration rate; ACR, albumin creatinine ratio; hs-CRP, high sensitivity c-reactive protein.
Model 1 – Unadjusted.
Model 2 – Adjusted for age, race, sex, and geographic region or residence.
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Table 3
Prevalence ratios for refractory hypertension compared to all treated individuals with hypertension
Characteristic Prevalence ratio (95% confidence interval)
Model 1 Model 2
Age, 10 years 0.97 (0.75 – 1.24) 1.08 (0.85 – 1.39)
African American versus white 4.09 (2.33 – 7.18) 4.88 (2.79 – 8.72)
Male versus female 1.55 (1.00 – 2.42) 2.00 (1.24 – 3. 07)
Geographic Region
 Stroke belt versus non-belt 1.15 (0.73 – 1.81) 1.57 (0.94 – 2.63)
 Stroke buckle versus non-belt 1.37 (0.83 – 2.25) 2.02 (1.14 – 3.58)
Heart rate (bpm) 0.58 (0.37 – 0.92) 0.54 (0.35 – 0.84)
Body mass index (kg/m2) 1.34 (1.18 – 1.50) 1.36 (1.19 – 1.56)
Household income, <$20,000 1.52 (0.92 – 2.52) 1.28 (0.73 – 2.24)
<High school education 1.51 (0.89 – 2.58) 1.09 (0.62 – 1.94)
eGFR <60 ml/min/1.73m2 2.60 (1.60 – 4.22) 2.84 (1.69 – 4.79)
Albuminuria (ACR ≥30 mg/g) 4.67 (2.99 – 7.30) 4.02 (2.53 – 6.41)
Diabetes 4.52 (2.80 – 7.32) 3.62 (2.26 – 5.81)
hs-CRP 1.39 (0.87 – 2.24) 1.36 (0.83 – 2.21)
Left ventricular hypertrophy 1.98 (1.17 – 3.35) 1.63 (0.95 – 2.81)
Prior stroke 2.54 (1.47 – 4.38) 2.23 (1.29 – 3.85)
Prior coronary heart disease 2.58 (1.65 – 4.03) 2.85 (1.77 – 4.59)
Physical activity 0.73 (0.46 – 1.13) 0.70 (0.44 – 1.09)
Alcohol consumption 0.66 (0.39 – 1.10) 0.74 (0.43 – 1.25)
DASH diet score 0.90 (0.72 – 1.44) 0.98 (0.77 – 1.24)
Smoking status
 Never 1 (reference) 1 (reference)
 Past 0.96 (0.61 – 1.50) 0.93 (0.60 – 1.45)
 Current 0.82 (0.41 – 1.64) 0.72 (0.37 – 1.43)
Depressive symptoms 1.42 (0.78 – 2.57) 1.34 (0.73 – 2.49)
High medication adherence 0.69 (0.33 – 1.43) 0.74 (0.36 – 1.55)
BPM, beats per minute; eGFR, estimated glomerular filtration rate; ACR, albumin creatinine ratio; hs-CRP, high sensitivity c-reactive protein.
Model 1 – Unadjusted.
Model 2 – Adjusted for age, race, sex, and geographic region or residence.
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Table 4
Framingham 10-year coronary heart disease (CHD) and stroke risk scores for individuals with refractory
hypertension, resistant hypertension and treated hypertension.
Characteristic Refractory Resistant Treated
10-year CHD risk* 17.5 (10.0 – 26.0) 11.7 (6.4 – 19.7) 7.9 (4.2 – 14.3)
Difference in 10-year CHD risk†
Refractory vs. resistant hypertension Reference 4.0(0.8–7.2)‡
Refractory vs. all treated hypertension Reference 7.0 (4.6 – 9.5)§
10-year stroke risk† 20.8 (12.9 – 31.3) 16.2 (9.2 – 26.8) 9.5 (5.3 – 17.0)
Difference in 10-year stroke risk†
Refractory vs. resistant hypertension Reference 5.1 (1.8 – 8.5)∥
Refractory vs. all treated hypertension Reference 8.1 (5.9 – 10.3)§
Individuals with prevalent CHD at baseline were excluded from the 10-year CHD risk calculation. Individuals with prevalent stroke at baseline
were excluded from the 10-year CHD risk calculation.
*
Median (25% - 75%).
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